Literature DB >> 10985330

HIV-1 genetic variability in Cameroon.

L Heyndrickx1, W Janssens, P M Ndumbe, K Vereecken, S Coppens, K De Houwer, K Fransen, G Van der Auwera, G van der Groen.   

Abstract

Entities:  

Mesh：

Year:  2000        PMID： 10985330     DOI： 10.1097/00002030-200008180-00028

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  5 in total

1.  Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade a and clade B v3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking.

Authors:  Chavdar Krachmarov; Abraham Pinter; William J Honnen; Miroslaw K Gorny; Phillipe N Nyambi; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  The Evolution of HIV-1 Diversity in Rural Cameroon and its Implications in Vaccine Design and Trials.

Authors:  Rebecca Powell; Denis Barengolts; Luzia Mayr; Phillipe Nyambi
Journal:  Viruses       Date:  2010-02-12       Impact factor: 5.048

Review 3.  Evolution and diversity of HIV-1 in Africa--a review.

Authors:  Maria A Papathanasopoulos; Gillian M Hunt; Caroline T Tiemessen
Journal:  Virus Genes       Date:  2003       Impact factor: 2.332

4.  The predominance of Human Immunodeficiency Virus type 1 (HIV-1) circulating recombinant form 02 (CRF02_AG) in West Central Africa may be related to its replicative fitness.

Authors:  Harr F Njai; Youssef Gali; Guido Vanham; Claude Clybergh; Wim Jennes; Nicole Vidal; Christelle Butel; Eitel Mpoudi-Ngolle; Martine Peeters; Kevin K Ariën
Journal:  Retrovirology       Date:  2006-07-03       Impact factor: 4.602

5.  Lipid peroxidation and total cholesterol in HAART-naïve patients infected with circulating recombinant forms of human immunodeficiency virus type-1 in Cameroon.

Authors:  Georges Teto; Georgette D Kanmogne; Judith N Torimiro; George Alemnji; Flore N Nguemaim; Désiré Takou; Aubin Nanfack; Asonganyi Tazoacha
Journal:  PLoS One       Date:  2013-06-07       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.